PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Zepatier (Elbasvir and Grazoprevir)

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Select the requested drug and regimen.

- ☐ Zepatier x 12 weeks
- ☐ Zepatier PLUS Ribavirin x 12 weeks
- ☐ Zepatier PLUS Ribavirin x 16 weeks
- ☐ Other [specify drug name(s), strength(s), regimen, duration]

Q2. Specify the prescriber's specialty.

- ☐ Hepatologist
- ☐ Board Certified Infectious Disease Specialist
- ☐ Board Certified Gastroenterologist
- ☐ Other (please specify)

Q3. Is the patient greater than or equal to 18 years of age?

☐ Yes ☐ No

Q4. What is the patient's diagnosis?

- ☐ Genotype 1a chronic HCV (or MIXED genotype 1a and 1b)
- ☐ Genotype 1b chronic HCV

Scott&White HEALTH PLAN
PART OF BAYLOR SCOTT & WHITE HEALTH

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Zepatier (Elbasvir and Grazoprevir)

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

☐ Genotype 2 chronic HCV
☐ Genotype 3 chronic HCV
☐ Genotype 4 chronic HCV
☐ Other (please specify)

Q5. Please provide ICD code(s) for diagnosis

Q6. If genotype 1a is there confirmation via FDA-approved test of the presence or absence of baseline NS5A treatment resistance-associated polymorphisms (M28, Q30, L31 or Y93)?

☐ Yes (Please provide documentation of FDA approved testing)
☐ No

Q7. Please provide most recent chart note, labs, genotype testing, baseline viral load, fibrosis testing, polymorphism testing, and any additional documentation that may be beneficial to pharmacist and medical director during the prior authorization case review.

Q8. Does the patient have an HCV RNA less than 6 million IU / ml?

☐ Yes ☐ No ☐ Unknown

Q9. What is the patient's Metavir score?

☐ Metavir score F0
☐ Metavir score F1
☐ Metavir score F2
☐ Metavir score F3 (advanced fibrosis)
☐ Metavir score F4 (cirrhosis)
☐ Unknown

Q10. How was the patient's Metavir score confirmed? [NOTE: Examples of non-invasive tests include: APRI, FIB-4, FibroIndex, Forns Index, HepaScore/FibroScore, FibroSure, cirrhosis on imaging, ShearWave Elastography, FibroScan, magnetic resonance elastography]

☐ Liver biopsy
☐ TWO non-invasive tests
☐ None of the above

Scott&White HEALTH PLAN
PART OF BAYLOR SCOTT & WHITE HEALTH

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Zepatier (Elbasvir and Grazoprevir)

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Q11. I have included documentation of the liver biopsy or TWO non-invasive tests used to determine the patient's Metavir score.

☐ Yes ☐ No

Q12. Select any of the diagnoses below that apply to this patient:

- ☐ Cryoglobulinemia AND either vasculitis, peripheral neuropathy, OR Reynaud's phenomenon
- ☐ Membranoproliferative glomerulonephritis
- ☐ Membranous nephropathy
- ☐ None of the above

Q13. Does the patient have hepatocellular carcinoma (HCC) meeting MILAN criteria, AND is the patient on the liver transplant list?

☐ Yes ☐ No

Q14. Provide MELD score, blood type, and duration of time that patient has been on the transplant list.

Q15. Select any of the following that apply to this patient.

- ☐ Genotype 1a HCV with baseline NS5A treatment resistance-associated polymorphisms, with prior protease inhibitor treatment experience (e.g. boceprevir, teleprevir)
- ☐ Moderate or severe hepatic impairment (Child-Pugh class B or C)
- ☐ Prior organ transplant, currently taking immunosuppressive agents
- ☐ Concurrent use of ANY of the following: efavirenz OR strong inducers of CYP3A4 (e.g. carbamazepine, phenytoin, rifampin, St. John's Wort) OR OATP1B1/3 inhibitors (e.g. atazanavir, cyclosporine, darunavir, lopinavir, saquinavir, tipranavir)
- ☐ Any other non-liver related comorbidity resulting in less than a 10-year predicted survival
- ☐ Ongoing non-adherence to prior medications or medical treatment
- ☐ Failure to complete HCV disease evaluation, appointments and procedures (e.g. laboratories)
- ☐ None of the above

Q16. Has the patient been abstinent from alcohol and IV drug use for the previous 6 months?

☐ Yes ☐ No

Q17. Select the agents that the patient has been treated with previously:

- ☐ Treatment naive

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Zepatier (Elbasvir and Grazoprevir)

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

- ☐ Peginterferon and Ribavirin (Dual Therapy)
- ☐ Daclatasvir (Daklinza)
- ☐ Dasabuvir (Viekira)
- ☐ Elbasvir (Zepatier)
- ☐ Grazoprevir (Zepatier)
- ☐ Ledipasvir (Harvoni)
- ☐ Ombitasvir (Viekira, Technivie)
- ☐ Paritaprevir (Technivie, Viekira)
- ☐ Simeprevir (Olysio)
- ☐ Sofosbuvir (Sovaldi or Harvoni)
- ☐ Other (Please Specify)

Q18. Please provide clinical justification as to why the preferred agent, Harvoni, is not appropriate for this patient.

Q19. Additional Comments

Prescriber Signature

Date

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Zepatier (Elbasvir and Grazoprevir)

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**